Addressing Unmet Medical Needs Through Tailored Vaccine Design: The Importance of Adjuvant Systems - It is now possible to combine antigens with specific adjuvant systems to create more-effective vacc


Addressing Unmet Medical Needs Through Tailored Vaccine Design: The Importance of Adjuvant Systems
It is now possible to combine antigens with specific adjuvant systems to create more-effective vaccines.

BioPharm International Supplements


1. Glenny AT, Buttle GAH, Stevens MF. Rate of disappearance of diphtheria toxoid injected into rabbits and guinea pigs: toxoid precipitated with alum. J Pathol. 1931;34:267–75.

2. Garçon N, Van Mechelen M, Wettendorff M. Development and evaluation of AS04, a novel and improved immunological adjuvant system containing MPL and aluminium salt. In: Schijns V, O'Hagan D, editors. Immunopotentiators in Modern Vaccines. London: Elsevier Academic Press; 2006: p. 161–77.

3. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: Concepts, achievements and perspectives. Expert Rev Vaccines. 2007;6(5):723–39.

4. World Health Organization. Recommendations of the strategic advisory group of experts (SAGE) on influenza A (H1N1) vaccines 19 May 2009 [cited 2009 Jul 3]. Available from: .

5. Centers for Disease Control and Prevention. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine [cited 2009 Jul 3]. Available from:

6. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007;370(9587):580–9.

7. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006;354(13):1343–51.

8. de Jong JC, Rimmelzwaan GF, Fouchier RAM, Osterhaus ADME. Influenza virus: A master of metamorphosis. J Infect. 2000;40(3):218–28.

9. Baras B, Stittelaar KJ, Simon JH, et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE. 2008;3(1):e1401.

10. Leroux-Roels I, Bernhard R, Gerard P, Drame M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE. 2008;3(2):e1665.

11. Ballester A, Garcés-Sanches M, Planelles Cantinaro M, et al. Pediatric safety evalation of an AS-adjuvanted H5N1 prepandemic candidate vaccine in children aged 3-9 years. A Phase II study. Presented at: 13th International Congress of Infectious Diseases; 19–22 June 2008; Kuala Lumpur, Malaysia.

12. Heijmans S, De Meulemeester M, Reynders P, et al. AS03 adjuvanted prepandemic influenza vaccine: High immunogenicity in the elderly. Presented at: 2nd Vaccine Congress; 7–9 December 2008; Boston, MA, USA.

13. Schwarz TF, Horacek T, Knuf M, et al. Single-dose primary vaccination with AS03-adjuvanted prepandemic H5N1 vaccine is sufficient to induce strong, rapid and broad immune response to booster vaccination after 12 months. Abstract presented at Influenza Vaccines for the World (IVW) Congress of Infectious Diseases; 27–30 April 2009; Cannes, France.

14. Chu DS, Dramé M, Hwang SJ., et al. Safety and immunogenicity of an AS adjuvanted H5N1 prepandemic influenza vaccine: a Phase III study in a large population of Asian adults. Abstract presented at: Xth International Symposium on Respiratory Viral Infections; 28 Feb–1 March 2008; Singapore.

15. Rümke HC, Bayas JM, de Juanes JR, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a Phase 3 safety trial. Vaccine. 2008;26(19):2378–88.

16. GLOBOCAN 2002 Cancer incidence, mortality and prevalence worldwide. Lyon: IARC Press, 2004.

17. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.

18. Stanley M. Immune responses to human papillomavirus. Vaccine. 2006;24(Supplement 1):S16–S22.

19. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol. 1996;70(2):960–5.

20. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A. 1995;92(25):11553-7.

21. Nardelli-Haefliger D, Wirthner D, Schiller JT, et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst. 2003;95(15):1128–37.

22. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006;24(33-34):5937–49.

23. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009;5(10); (in press).

24. Wheeler CM, Teixeira J, Romanowski B, De Carvalho N, Dubin G, Schuind A. High and sustained HPV-16 and 18 antibody levels through 6.4 years in women vaccinated with Cervarix (GSK HPV-16/18 AS04 vaccine). Abstract presented at: 26th Annual Meeting of the European Society for Paediatric Infectious Diseases; 13–17 May 2008; Graz, Austria.

25. Harper D, Gall S, Naud P, et al. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: Long-term follow up through 6.4 years in women vaccinated with Cervarix (GSK's HPV 16/18 AS04 candidate vaccine). Gynecol Oncol.109(1):158–9.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here